Current and future challenges in HCV: insights from an Italian experts panel.
Infection
; 46(2): 147-163, 2018 Apr.
Article
em En
| MEDLINE
| ID: mdl-29098647
ABSTRACT
BACKGROUND:
The recent availability of direct acting antiviral drugs (DAAs) has drastically changed hepatitis C virus (HCV) treatment scenarios, due to the exceedingly high rates of sustained virological response (SVR) and excellent tolerability allowing for treatment at all disease stages.METHODS:
A panel of Italian experts was convened twice, in November 2016 and January 2017, to provide further support on some open issues and provide guidance for personalized HCV care, also in light of forthcoming regimens. RESULTS ANDCONCLUSIONS:
Treatment recommendations issued by international and national liver societies to guide clinicians in the management of HCV infection are constantly updated due to accumulating new data. Such recommendations may not be applicable to all healthcare settings for a variety of reasons. Moreover, some gaps still remain and the spectrum of patients to be treated is also evolving.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Hepatite C
Tipo de estudo:
Guideline
Limite:
Humans
País/Região como assunto:
Europa
Idioma:
En
Revista:
Infection
Ano de publicação:
2018
Tipo de documento:
Article
País de afiliação:
Itália